PV Bulletin

Spikevax (previously COVID-19 Vaccine Moderna) Labeling Update

New updates regarding Spikevax vaccine adaptations to evolving SARS-CoV-2 variants.

Primary source: Recommendation to include myocarditis and pericarditis as side effects in product information

PV Impact Brief

Urgency: HighConfidence: high

What changed

Labeling has been updated to include specific information about the adaptations of Spikevax to target new SARS-CoV-2 variants, including the use of adapted vaccines like the bivalent Original/Omicron BA.1 and BA.4-5.

Why it matters

Keeping the labeling up-to-date ensures that healthcare professionals and the public are informed about the most effective vaccine preparations against current variants of COVID-19, ultimately enhancing public health responses.

Action needed

Regulatory teams should integrate the new labeling information into their literature surveillance processes to ensure compliance and accurate communication surrounding Spikevax usage.

Relevant for
Labeling Lead
Processes impacted
Literature Surveillance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Evidence and confidence

Confidence: highSource updated: Aug 26, 2026

Full briefing

Practical implication

Regulatory teams should integrate the new labeling information into their literature surveillance processes to ensure compliance and accurate communication surrounding Spikevax usage.

The European Medicines Agency (EMA) has updated the labeling for Spikevax, detailing its adaptations targeting the most recent strains of SARS-CoV-2, including the bivalent Original/Omicron BA.1 and BA.4-5 vaccines. This update reflects the continuous evolution of the virus and aims to maintain vaccine efficacy and protection against COVID-19.

What changed: Labeling has been updated to include specific information about the adaptations of Spikevax to target new SARS-CoV-2 variants, including the use of adapted vaccines like the bivalent Original/Omicron BA.1 and BA.4-5.

Why it matters: Keeping the labeling up-to-date ensures that healthcare professionals and the public are informed about the most effective vaccine preparations against current variants of COVID-19, ultimately enhancing public health responses.

Practical implication: Regulatory teams should integrate the new labeling information into their literature surveillance processes to ensure compliance and accurate communication surrounding Spikevax usage.

View original source

  • Source: EMA - What's new RSS
  • Published at source: 2026-08-26T00:00:00.000Z
  • Discovered by monitor: 2026-08-26T22:30:49.188Z

Published from the regulator source ingestion pipeline after PV impact triage.

#Labeling#Safety Signals#Source-ingestion#Regulator-monitor#European Union#Ema.europa.eu

Related updates for your role

publicEMA · European Union · Updated Sep 7, 2026

Co-ordinating good manufacturing practice (GMP) inspections for centrally authorised products

Urgency: High

Ensure all sites listed in marketing authorization applications are ready for inspection upon submission, and adhere to the new timelines for inspection requests and report submissions.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Sep 4, 2026

New EU supply chain to end Visudyne shortage

Urgency: High

Monitor the supply chain developments and prepare to adjust inventory management practices as the end of the shortage approaches.

Signal ManagementSignal Management Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Signal Management Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Sep 4, 2026Translated From French

Parenteral iron-containing medicinal products - referral

Urgency: High

Monitor for changes in labeling requirements and risk management strategies as a result of the ongoing review by PRAC.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Sep 4, 2026Translated From French

PRAC 3 September 2026: Starts safety review of injectable iron-containing medicines Image credit: © tadamichi | stock.adobe.com Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 31 August - 3 September 2026 4 September 20

Urgency: High

Signal management teams need to prepare for potential updates in labeling, usage guidelines, and monitoring requirements for injectable iron-containing medicines.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward